Molecular imaging of the tumor microenvironment for precision medicine and theranostics.

Morbidity and mortality from cancer and their associated conditions and treatments continue to extract a heavy social and economic global burden despite the transformative advances in science and technology in the twenty-first century. In fact, cancer incidence and mortality are expected to reach pandemic proportions by 2025, and costs of managing cancer will escalate to trillions of dollars. The inability to establish effective cancer treatments arises from the complexity of conditions that exist within tumors, the plasticity and adaptability of cancer cells coupled with their ability to escape immune surveillance, and the co-opted stromal cells and microenvironment that assist cancer cells in survival. Stromal cells, although destroyed together with cancer cells, have an ever-replenishing source that can assist in resurrecting tumors from any residual cancer cells that may survive treatment. The tumor microenvironment landscape is a continually changing landscape, with spatial and temporal heterogeneities that impact and influence cancer treatment outcome. Importantly, the changing landscape of the tumor microenvironment can be exploited for precision medicine and theranostics. Molecular and functional imaging can play important roles in shaping and selecting treatments to match this landscape. Our purpose in this review is to examine the roles of molecular and functional imaging, within the context of the tumor microenvironment, and the feasibility of their applications for precision medicine and theranostics in humans.

[1]  P. Antich,et al.  In vivo oxygen tension and temperature: Simultaneous determination using 19F NMR spectroscopy of perfluorocarbon , 1993, Magnetic resonance in medicine.

[2]  Ralph Weissleder,et al.  Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. , 2003, The New England journal of medicine.

[3]  S. Caruthers,et al.  Three‐dimensional MR mapping of angiogenesis with α5β1(αvβ3)‐targeted theranostic nanoparticles in the MDA‐MB‐435 xenograft mouse model , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  F. O’Sullivan,et al.  Regional Hypoxia in Glioblastoma Multiforme Quantified with [18F]Fluoromisonidazole Positron Emission Tomography before Radiotherapy: Correlation with Time to Progression and Survival , 2008, Clinical Cancer Research.

[5]  Pernille R. Jensen,et al.  Magnetic resonance imaging of pH in vivo using hyperpolarized 13C-labelled bicarbonate , 2008, Nature.

[6]  Silvio Aime,et al.  Combined delivery and magnetic resonance imaging of neural cell adhesion molecule-targeted doxorubicin-containing liposomes in experimentally induced Kaposi's sarcoma. , 2010, Cancer research.

[7]  U. Weidle,et al.  Proteases as activators for cytotoxic prodrugs in antitumor therapy. , 2014, Cancer genomics & proteomics.

[8]  D. Quail,et al.  Microenvironmental regulation of tumor progression and metastasis , 2014 .

[9]  V. Grégoire,et al.  A prospective clinical study of 18 F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  Paolo P. Provenzano,et al.  Collagen reorganization at the tumor-stromal interface facilitates local invasion , 2006, BMC medicine.

[11]  Qiang Zhang,et al.  LyP-1 modification to enhance delivery of artemisinin or fluorescent probe loaded polymeric micelles to highly metastatic tumor and its lymphatics. , 2012, Molecular pharmaceutics.

[12]  Meng Yang,et al.  Activatable near-infrared fluorescent probe for in vivo imaging of fibroblast activation protein-alpha. , 2012, Bioconjugate chemistry.

[13]  Thorsten Persigehl,et al.  Optical techniques for the molecular imaging of angiogenesis , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  P. Low,et al.  Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results , 2011, Nature Medicine.

[15]  A. Vahrmeijer,et al.  Image-guided cancer surgery using near-infrared fluorescence , 2013, Nature Reviews Clinical Oncology.

[16]  Dai Fukumura,et al.  Tumor microenvironment abnormalities: Causes, consequences, and strategies to normalize , 2007, Journal of cellular biochemistry.

[17]  S. Zhou,et al.  Feasibility of MR imaging in evaluating breast cancer lymphangiogenesis using Polyethylene glycol-GoldMag nanoparticles. , 2013, Clinical radiology.

[18]  V Ntziachristos,et al.  Real-time near infrared fluorescence (NIRF) intra-operative imaging in ovarian cancer using an α(v)β(3-)integrin targeted agent. , 2013, Gynecologic oncology.

[19]  E. Rummeny,et al.  In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging , 2004, European Radiology.

[20]  Shan X. Wang,et al.  Fluorescent magnetic nanoparticles for magnetically enhanced cancer imaging and targeting in living subjects. , 2012, ACS nano.

[21]  C. Ling,et al.  In vivo19F Magnetic Resonance Spectroscopy and Chemical Shift Imaging of Tri-Fluoro-Nitroimidazole as a Potential Hypoxia Reporter in Solid Tumors , 2007, Clinical Cancer Research.

[22]  M. Berger,et al.  Longitudinal evaluation of MPIO-labeled stem cell biodistribution in glioblastoma using high resolution and contrast-enhanced MR imaging at 14.1 tesla. , 2012, Neuro-oncology.

[23]  M O Leach,et al.  A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopy , 2009, British Journal of Cancer.

[24]  M. Coffey,et al.  Hypoxia response element‐driven cytosine deaminase/5‐fluorocytosine gene therapy system: a highly effective approach to overcome the dynamics of tumour hypoxia and enhance the radiosensitivity of prostate cancer cells in vitro , 2009, The journal of gene medicine.

[25]  H. Fine,et al.  Noninvasive MR imaging of magnetically labeled stem cells to directly identify neovasculature in a glioma model. , 2005, Blood.

[26]  L. H. Gray,et al.  The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy , 1955, British Journal of Cancer.

[27]  M. Ferraretto,et al.  MRI evaluation of the antitumor activity of paramagnetic liposomes loaded with prednisolone phosphate. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[28]  Andrei Iagaru,et al.  Imaging tumor angiogenesis: the road to clinical utility. , 2013, AJR. American journal of roentgenology.

[29]  Manojit Pramanik,et al.  Molecular photoacoustic imaging of angiogenesis with integrin‐targeted gold nanobeacons , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[30]  Brian O'Rourke,et al.  Hypoxic tumor microenvironments reduce collagen I fiber density. , 2010, Neoplasia.

[31]  Hisataka Kobayashi,et al.  Cancer Cell-Selective In Vivo Near Infrared Photoimmunotherapy Targeting Specific Membrane Molecules , 2011, Nature Medicine.

[32]  G. Melillo,et al.  Development of HIF-1 inhibitors for cancer therapy , 2009, Journal of cellular and molecular medicine.

[33]  M. Solaiyappan,et al.  Hypoxic Tumor Environments Exhibit Disrupted Collagen I Fibers and Low Macromolecular Transport , 2013, PloS one.

[34]  Gregory S Karczmar,et al.  MRI of the tumor microenvironment , 2002, Journal of magnetic resonance imaging : JMRI.

[35]  U. Sharma,et al.  Potential of magnetic resonance spectroscopy to detect metastasis in axillary lymph nodes in breast cancer. , 2005, Magnetic resonance imaging.

[36]  Kristine Glunde,et al.  Exploiting the tumor microenvironment for theranostic imaging , 2011, NMR in biomedicine.

[37]  Zaver M. Bhujwalla,et al.  In Vivo “MRI Phenotyping” Reveals Changes in Extracellular Matrix Transport and Vascularization That Mediate VEGF-Driven Increase in Breast Cancer Metastasis , 2013, PloS one.

[38]  Kevin M Brindle,et al.  Monitoring T‐lymphocyte trafficking in tumors undergoing immune rejection , 2005, Magnetic resonance in medicine.

[39]  Xunbin Wei,et al.  Imaging acidosis in tumors using a pH-activated near-infrared fluorescence probe. , 2012, Chemical communications.

[40]  Ick Chan Kwon,et al.  Tumoral acidic extracellular pH targeting of pH-responsive MPEG-poly(beta-amino ester) block copolymer micelles for cancer therapy. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[41]  GdDO3NI, a nitroimidazole-based T1 MRI contrast agent for imaging tumor hypoxia in vivo , 2014, JBIC Journal of Biological Inorganic Chemistry.

[42]  Vittorio Cristini,et al.  Mechanistic patient-specific predictive correlation of tumor drug response with microenvironment and perfusion measurements , 2013, Proceedings of the National Academy of Sciences.

[43]  D. S. Lee,et al.  Environmental pH-sensitive polymeric micelles for cancer diagnosis and targeted therapy. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[44]  Robert J. Gillies,et al.  Causes and Consequences of Increased Glucose Metabolism of Cancers , 2008, Journal of Nuclear Medicine.

[45]  M. Neeman,et al.  Ovarian carcinoma: quantitative biexponential MR imaging relaxometry reveals the dynamic recruitment of ferritin-expressing fibroblasts to the angiogenic rim of tumors. , 2013, Radiology.

[46]  S. Caruthers,et al.  Minute dosages of ανβ3‐targeted fumagillin nanoparticles impair Vx‐2 tumor angiogenesis and development in rabbits , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[47]  Meiyappan Solaiyappan,et al.  Collagen I fiber density increases in lymph node positive breast cancers: pilot study , 2012, Journal of biomedical optics.

[48]  Dmitri Artemov,et al.  Nanoplex delivery of siRNA and prodrug enzyme for multimodality image-guided molecular pathway targeted cancer therapy. , 2010, ACS nano.

[49]  Brian Seed,et al.  Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation , 2003, Nature Medicine.

[50]  M. Pomper,et al.  PSMA-targeted theranostic nanoplex for prostate cancer therapy. , 2012, ACS nano.

[51]  Anna Moore,et al.  In vivo imaging of siRNA delivery and silencing in tumors , 2007, Nature Medicine.

[52]  S. Caruthers,et al.  Molecular MR imaging of neovascular progression in the Vx2 tumor with αvβ3-targeted paramagnetic nanoparticles. , 2013, Radiology.

[53]  Pilar López-Larrubia,et al.  Serial in vivo spectroscopic nuclear magnetic resonance imaging of lactate and extracellular pH in rat gliomas shows redistribution of protons away from sites of glycolysis. , 2007, Cancer research.

[54]  Bonnie F. Sloane,et al.  Bicarbonate increases tumor pH and inhibits spontaneous metastases. , 2009, Cancer research.

[55]  R. Weissleder,et al.  Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy. , 2009, Clinical imaging.

[56]  Arvind P Pathak,et al.  Characterizing vascular parameters in hypoxic regions: a combined magnetic resonance and optical imaging study of a human prostate cancer model. , 2006, Cancer research.

[57]  Martin G Pomper,et al.  Targeting collagen strands by photo-triggered triple-helix hybridization , 2012, Proceedings of the National Academy of Sciences.

[58]  G. Semenza Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics , 2010, Oncogene.

[59]  M. Pagel,et al.  Evaluations of extracellular pH within in vivo tumors using acidoCEST MRI , 2014, Magnetic resonance in medicine.

[60]  L. H. Gray,et al.  The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. , 1953, The British journal of radiology.

[61]  Natarajan Raghunand,et al.  In vivo imaging of extracellular pH using 1H MRSI , 1999, Magnetic resonance in medicine.

[62]  T. Duong,et al.  Longitudinal study of tumor‐associated macrophages during tumor expansion using MRI , 2011, NMR in biomedicine.

[63]  R. Mason,et al.  Novel 1H NMR approach to quantitative tissue oximetry using hexamethyldisiloxane , 2006, Magnetic resonance in medicine.

[64]  M. Wendland,et al.  MRI of Tumor-Associated Macrophages with Clinically Applicable Iron Oxide Nanoparticles , 2011, Clinical Cancer Research.

[65]  R. Gillies,et al.  Hypoxia and adaptive landscapes in the evolution of carcinogenesis , 2007, Cancer and Metastasis Reviews.

[66]  R. Jain Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  Hanwen Zhang,et al.  A Comparison of the Imaging Characteristics and Microregional Distribution of 4 Hypoxia PET Tracers , 2014, The Journal of Nuclear Medicine.

[68]  Michal Neeman,et al.  In vivo imaging of the systemic recruitment of fibroblasts to the angiogenic rim of ovarian carcinoma tumors. , 2007, Cancer research.

[69]  A. Pathak,et al.  MR molecular imaging of tumor vasculature and vascular targets. , 2010, Advances in genetics.